Profile:
|
The Randomized Cycle Three Research associated with Pembrolizumab Compared to Pembrolizumab-Carboplatin-Doxorubicin with regard to In the area Advanced or even Metastatic Nonsquamous Non-small-cell Cancer of the lung using PD-L1 50% or even more (LAPLACE-50): Research Standard protocol
|